A. Bauer et al., Smallest region of overlapping deletion in I p36 in human neuroblastoma: AI Mbp cosmid and PAC contig, GENE CHROM, 31(3), 2001, pp. 228-239
In human neuroblastomas, the distal portion of Ip is frequently deleted, as
if one or more tumor suppressor genes from this region were involved in ne
uroblastoma tumorigenesis. Earlier studies had identified a smallest region
of overlapping deletion (SRO) spanning approximately 23 cM between the mos
t distally retained DIS80 and by the proximally retained DIS244. In pursuit
of generating a refined delineation of the minimally deleted region, we ha
ve analyzed 49 neuroblastomas of different stages for loss of heterozygosit
y (LOH) from Ipter to Ip35 by employing 26 simple sequence length polymorph
isms. Fifteen of the 49 tumors (31%) had LOH; homozygous deletion was not d
etected. Seven tumors had LOH at all informative loci analyzed, and eight t
umors showed a terminal or an interstitial allelic loss of Ip. One small te
rminal and one interstitial deletion defined a new 1.7 cM SRO, approximatel
y I Mbp in physical length, deleted in all tumors between the retained DIS2
731 (distal) and DIS2666 (proximal). To determine the genomic complexity of
the deleted region shared among tumors, we assembled a physical map of the
I Mbp SRO consisting predominantly of bacteriophage PI-derived artificial
chromosome (PAC) clones. A total of 55 sequence-tagged site (STS) markers (
23 published STSs and short tandem repeats and 32 newly identified STSs fro
m the insert ends of PACs and cosmids) were assembled in a contig, resultin
g in a sequence-ready physical map with approximately one STS per 20 Kbp. T
welve genes (41BE, CD30, DFFA, DJI, DR3, FRAP, HKR3, MASP2, MTHFR, RIZ, TNR
2, TP73) previously mapped to Ip36 are localized outside this SRO. On the b
asis of this study, they would be excluded as candidate genes for neuroblas
toma tumorigenesis. Ten expressed sequence tags were integrated in the cont
ig, of which five are Located outside the SRO. The other five from within t
he SRO may provide an entrance point for the cloning of candidate genes for
neuroblastoma. (C) 2001 Wiley-Liss, Inc.